$XBI $68.46 | -0.2%
Table of Contents:
Covid Updates
$VALN -20.6% Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement. source
$VALN -20.6% Valneva Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine. source
Pipeline Updates
$AVTE -11.3% Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) source
$GILD -0.2% FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV source
$AGTC +2.6% AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa source
$CCCC -6.2% C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDACâ„¢ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors. source
$LNTH +4.5% Lantheus Presents Results from a PYLARIFY AIâ„¢ Study at the American Urological Association (AUA) Annual Meeting. source
$NLTX +11.2% Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab). source
$ATNX -0.6% Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC). source
$DYN +0.5% Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown. source
$SCPH +5.6% scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application. source
$GRTX +13.3% Galera Announces Plan to Submit Avasopasem NDA by Year End. source
$EBS -0.4% Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages. source
$CMRX -60.9% Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties. source
$XFOR +3.3% X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor. source
$RCKT -0.3% Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). source
$PHAS -11.4% PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab. source
$ANGN -1.5% Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis. source
$TVTX +6.1% Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy. source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$BFRI -5.4% Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement. source
$KMPH +7.1% KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline. source
$ORPH -5.3% Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.. source
$APRE -19.1% Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results. source
Posted by FS/JM